21 varieties of China Resources Sanjiu have sold over 100 million yuan, and 1 new drug has attacked the market of 100 billion yuan

Recently, Hefei China Resources Shenlu Pharmaceutical, a subsidiary of China Resources Sanjiu, submitted a new Chinese medicine drug Taohong Siwu Granules for listing, which is the first new traditional Chinese medicine for gynecological menstruation reported for delivery in the past five years
.
CR Sanjiu is mainly engaged in self-diagnosis and prescription drugs.
In 2020, the sales of 21 varieties exceeded 100 million yuan, and many OTC varieties are in a leading position in the same category
.
In recent years, the company has continued to increase investment in research and development.
It is mainly engaged in the research and development of new traditional Chinese medicine drugs to focus on advantageous fields.
The first class of new chemical drugs has developed into an anti-tumor drug market of 100 billion yuan; It has been included in the national mining and all the bids have been won, and the first 6 varieties have been evaluated
.
21 varieties have sold over 100 million yuan, and formula granules have sold over 2 billion yuan.
China Resources Sanjiu is a traditional Chinese medicine and OTC platform under China Resources Group, with self-medication (CHC) and prescription drugs (RX) as its main business.
one
.
In addition, the company is a pilot enterprise of traditional Chinese medicine formula granules.
At present, it has produced more than 600 varieties of single-flavor formula granules, and its revenue in 2020 will exceed 2 billion yuan
.
2017-2021H1 performance of China Resources Sanjiu (unit: 100 million yuan) Source: Announcement of listed companies From the perspective of business segments, CHC business covers nearly 10 categories such as colds, skin, gastrointestinal, orthopedics, pediatrics, hepatobiliary, etc.
Revenue has continued to rise, from 5.
429 billion yuan in 2017 to 7.
834 billion yuan in 2020, and has now become the main source of income for China Resources Sanjiu
.
The RX business covers oncology, cardiovascular and cerebrovascular, digestive, orthopedics, pediatrics and other therapeutic fields, and the specialty line and traditional Chinese medicine formula granules business are growing rapidly
.
With the liberalization of the traditional Chinese medicine formula granule policy, China Resources Sanjiu can further expand more terminals while improving the efficiency of existing terminals.
In addition, there is room for improvement in the replacement rate of traditional decoction pieces.
The company expects this business to be realized in the next 2-3 years.
Better growth
.
Affected by the policy, the company's anti-infection business has declined, but through product structure adjustment and new products, it is expected to achieve double-digit growth in 2022
.
According to the data from Minet.
com, in 2021E China's urban physical pharmacy terminals, CR Sanjiu is expected to have a number of OTC varieties in the leading position, including Chinese patent medicine Ganmaoling granules, stomach medicine Chinese patent medicine Sanjiu Weitai granules, mineral supplements Calcium and zinc gluconate oral solution,
etc.
Sales of some products of China Resources Sanjiu in Chinese urban physical pharmacy terminals (unit: 100 million yuan) Source: Minet.
com Competition pattern of Chinese urban physical pharmacy terminals In terms of Chinese patent medicines, Ganmaoling Granules has ranked first in the best-selling list of Chinese patent medicines for colds for many consecutive years.
About 30 domestic companies have the drug approval for this product
.
China Resources Sanjiu's Ganmaoling Granules exceeded 2 billion yuan for the first time in 2019, becoming the first and only Chinese patent medicine brand for colds with annual sales exceeding 2 billion yuan.
The sales in 2021 are expected to be close to 2.
3 billion yuan
.
Sanjiu Weitai Granules is the exclusive variety of China Resources Sanjiu.
It ranks second only to Kangfuxin Liquid in the ranking of Chinese patent medicines for gastric medicine (gastritis and ulcer), but it has been ranked first in the brand ranking for many years, and it is the first Chinese patent medicine for gastric medicines in China.
first brand
.
In terms of chemical drugs, calcium and zinc gluconate oral solution is the leading calcium supplement product for children.
Since 2018, it has become the best-selling mineral supplement in China's urban physical pharmacy terminals, and has maintained double-digit sales growth in recent years
.
In 2020, Aonuo Pharmaceutical's calcium and zinc gluconate oral solution will replace Wyeth's calcium carbonate D3 tablets and become the first brand of mineral supplements.
It is expected that the sales in 2021 will exceed 1 billion yuan
.
In the terminals of public medical institutions in China, CR Sanjiu's exclusive varieties of Gutong paste and Qi stagnation and stomach pain granules have performed well
.
In the ranking of orthopaedic analgesic Chinese patent medicine products and brand rankings, Gutong plaster ranks third, and will rise to the second place in the first half of 2021; in the ranking of Chinese patent medicine products for gastric medicine (gastritis, ulcer), Qi stagnation stomachache Particles ranked third
.
Sales of some products of CR 39 in public medical institutions in China (unit: 100 million yuan) Source: Minet In the first three quarters, the company's research and development expenses were 355 million yuan, an increase of nearly 30% over the same period last year, accounting for more than 3% of operating income
.
In recent years, CR Sanjiu has continued to increase R&D investment and enrich its product pipeline
.
As of the end of 2020, the company has 57 research projects, focusing on oncology, orthopedics, skin, respiratory and other therapeutic fields
.
China Resources Sanjiu’s R&D expenses (unit: 100 million yuan) Note: excluding capitalized R&D investment Source: Listed company announcement On January 7, the official website of the State Food and Drug Administration showed that China Resources Jiuxin’s cefoxitin sodium for injection passed the consistency evaluation
.
According to the data of Minet.
com, 8 varieties of China Resources Sanjiu have passed or are deemed to have passed the consistency evaluation, and 3 of them are the first/exclusive evaluation, which are Zopiclone Tablets, Montmorillonite Granules and Aluminum Magnesium Carbonate Chewable Tablets
.
China Resources Sanjiu’s review status Note: With * has been included in the national centralized procurement Source: Minet.
com MED2.
0 China Drug Evaluation Database of the consistency evaluation varieties under review, 10 varieties were submitted for marketing/clinical applications under the new registration classification, Among them, no first copy of obeticholic acid tablets has been approved yet; 3 varieties have submitted supplementary applications for consistency evaluation, among which mizolastine sustained-release tablets and pidotimod tablets have not been approved or deemed to have passed the consistency evaluation
.
CR Sanjiu’s consistency evaluation varieties under review (including new classification declarations) Source: MED2.
0 China Drug Evaluation Database of Minet Imported 5.
1 class new drug cefbiproxil sodium for injection and 2.
2 class new drug mitoxantrone hydrochloride injection for tracer
.
Among them, cefbirol sodium for injection is the first approved fifth-generation cephalosporin antibiotic in China, which is conducive to enhancing the company's market competitiveness in the field of anti-infection
.
Source of some of the new drugs under development in China Resources Sanjiu: Minet.
com China Drug Clinical Trial Publicity Library Among the new drugs under development, the 3.
1 class new drug of traditional Chinese medicine Taohong Siwu Granules has recently been declared for the market.
It is used for irregular menstruation in women with blood deficiency and blood stasis.
Jinbuhuangutong Capsule is the first new traditional Chinese medicine for gynecological menstruation reported for delivery in the past 5 years; Jinbuhuangutong Capsule has entered the phase II clinical trial for knee osteoarthritis-cold-dampness blocking collaterals and blood stasis syndrome
.
In addition, CR Sanjiu pays attention to the inheritance and innovation of traditional Chinese medicine, and focuses on the research of classic Chinese medicine prescriptions, formula granule standards and medicinal material resources.
Currently, there are more than ten classic prescriptions under research, and some of the researched varieties have completed the application materials
.
In the field of chemical drugs, the two new Class 1 drugs under development are all anti-tumor drugs.
According to Minet.
com, the terminal anti-tumor drug market in China's public medical institutions will exceed 100 billion yuan in 2020
.
QBH-196 is a multi-targeted receptor tyrosine kinase inhibitor, and the indication for advanced malignant solid tumors has entered phase I clinical; the introduced ONC201 is a DRD2 antagonist/ClpP agonist, and the world's highest R&D progress is in II The clinical application in China has been accepted by CDE
.